143 related articles for article (PubMed ID: 35948163)
1. Glutaminyl cyclases, the potential targets of cancer and neurodegenerative diseases.
Zhang Y; Wang Y; Zhao Z; Peng W; Wang P; Xu X; Zhao C
Eur J Pharmacol; 2022 Sep; 931():175178. PubMed ID: 35948163
[TBL] [Abstract][Full Text] [Related]
2. Human glutaminyl cyclase: Structure, function, inhibitors and involvement in Alzheimer's disease.
Vijayan DK; Zhang KYJ
Pharmacol Res; 2019 Sep; 147():104342. PubMed ID: 31288079
[TBL] [Abstract][Full Text] [Related]
3. Structures of human Golgi-resident glutaminyl cyclase and its complexes with inhibitors reveal a large loop movement upon inhibitor binding.
Huang KF; Liaw SS; Huang WL; Chia CY; Lo YC; Chen YL; Wang AH
J Biol Chem; 2011 Apr; 286(14):12439-49. PubMed ID: 21288892
[TBL] [Abstract][Full Text] [Related]
4. Exploring the binding mode of PQ912 against secretory glutaminyl cyclase through systematic exploitation of conformational ensembles.
Chandran R; Dileep KV
Chem Biol Drug Des; 2021 Nov; 98(5):850-856. PubMed ID: 34423556
[TBL] [Abstract][Full Text] [Related]
5. Glutaminyl Cyclase, Diseases, and Development of Glutaminyl Cyclase Inhibitors.
Xu C; Wang YN; Wu H
J Med Chem; 2021 May; 64(10):6549-6565. PubMed ID: 34000808
[TBL] [Abstract][Full Text] [Related]
6. Glutaminyl cyclase in human cortex: correlation with (pGlu)-amyloid-β load and cognitive decline in Alzheimer's disease.
Morawski M; Schilling S; Kreuzberger M; Waniek A; Jäger C; Koch B; Cynis H; Kehlen A; Arendt T; Hartlage-Rübsamen M; Demuth HU; Roßner S
J Alzheimers Dis; 2014; 39(2):385-400. PubMed ID: 24164736
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical Evidence from APP-Transgenic Mice for Glutaminyl Cyclase as Drug Target to Diminish pE-Abeta Formation.
Hartlage-Rübsamen M; Bluhm A; Piechotta A; Linnert M; Rahfeld JU; Demuth HU; Lues I; Kuhn PH; Lichtenthaler SF; Roßner S; Höfling C
Molecules; 2018 Apr; 23(4):. PubMed ID: 29673150
[TBL] [Abstract][Full Text] [Related]
8. Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta.
Cynis H; Scheel E; Saido TC; Schilling S; Demuth HU
Biochemistry; 2008 Jul; 47(28):7405-13. PubMed ID: 18570439
[TBL] [Abstract][Full Text] [Related]
9. Piperidine-4-carboxamide as a new scaffold for designing secretory glutaminyl cyclase inhibitors.
Dileep KV; Sakai N; Ihara K; Kato-Murayama M; Nakata A; Ito A; Sivaraman DM; Shin JW; Yoshida M; Shirouzu M; Zhang KYJ
Int J Biol Macromol; 2021 Feb; 170():415-423. PubMed ID: 33373636
[TBL] [Abstract][Full Text] [Related]
10. N-terminal pyroglutamate formation in CX3CL1 is essential for its full biologic activity.
Kehlen A; Haegele M; Böhme L; Cynis H; Hoffmann T; Demuth HU
Biosci Rep; 2017 Aug; 37(4):. PubMed ID: 28739588
[TBL] [Abstract][Full Text] [Related]
11. A patent review of glutaminyl cyclase inhibitors (2004-present).
Coimbra JRM; Salvador JAR
Expert Opin Ther Pat; 2021 Sep; 31(9):809-836. PubMed ID: 33896339
[No Abstract] [Full Text] [Related]
12. X-ray Structure-Guided Discovery of a Potent Benzimidazole Glutaminyl Cyclase Inhibitor That Shows Activity in a Parkinson's Disease Mouse Model.
Mou J; Ning XL; Wang XY; Hou SY; Meng FB; Zhou C; Wu JW; Li C; Jia T; Wu X; Wu Y; Chen Y; Li GB
J Med Chem; 2024 Jun; 67(11):8730-8756. PubMed ID: 38817193
[TBL] [Abstract][Full Text] [Related]
13. Glutaminyl cyclases display significant catalytic proficiency for glutamyl substrates.
Seifert F; Schulz K; Koch B; Manhart S; Demuth HU; Schilling S
Biochemistry; 2009 Dec; 48(50):11831-3. PubMed ID: 19921850
[TBL] [Abstract][Full Text] [Related]
14. Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanisms.
Hartlage-Rübsamen M; Morawski M; Waniek A; Jäger C; Zeitschel U; Koch B; Cynis H; Schilling S; Schliebs R; Demuth HU; Rossner S
Acta Neuropathol; 2011 Jun; 121(6):705-19. PubMed ID: 21301857
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate A{beta} formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice.
Jawhar S; Wirths O; Schilling S; Graubner S; Demuth HU; Bayer TA
J Biol Chem; 2011 Feb; 286(6):4454-60. PubMed ID: 21148560
[TBL] [Abstract][Full Text] [Related]
16. Phosphate ions and glutaminyl cyclases catalyze the cyclization of glutaminyl residues by facilitating synchronized proton transfers.
Seifert F; Demuth HU; Weichler T; Ludwig HH; Tittmann K; Schilling S
Bioorg Chem; 2015 Jun; 60():98-101. PubMed ID: 25981125
[TBL] [Abstract][Full Text] [Related]
17. Identification of Glutaminyl Cyclase Genes Involved in Pyroglutamate Modification of Fungal Lignocellulolytic Enzymes.
Wu VW; Dana CM; Iavarone AT; Clark DS; Glass NL
mBio; 2017 Jan; 8(1):. PubMed ID: 28096492
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of glutaminyl cyclases: Current status and emerging trends.
Coimbra JRM; Moreira PI; Santos AE; Salvador JAR
Drug Discov Today; 2023 Oct; 28(10):103644. PubMed ID: 37244566
[TBL] [Abstract][Full Text] [Related]
19. Distinct glutaminyl cyclase expression in Edinger-Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Abeta pathology in Alzheimer's disease.
Morawski M; Hartlage-Rübsamen M; Jäger C; Waniek A; Schilling S; Schwab C; McGeer PL; Arendt T; Demuth HU; Rossner S
Acta Neuropathol; 2010 Aug; 120(2):195-207. PubMed ID: 20383514
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Potent Human Glutaminyl Cyclase Inhibitors as Anti-Alzheimer's Agents Based on Rational Design.
Hoang VH; Tran PT; Cui M; Ngo VT; Ann J; Park J; Lee J; Choi K; Cho H; Kim H; Ha HJ; Hong HS; Choi S; Kim YH; Lee J
J Med Chem; 2017 Mar; 60(6):2573-2590. PubMed ID: 28234463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
